Susquehanna Portfolio Strategies, LLC
Position in MLYS — Mineralys Therapeutics, Inc.
CIK 1996449
Bala Cynwyd, PA
Position in MLYS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,115,512
-$718,446 QoQ
Shares Held
78,092
0.0% QoQ
Ownership
0.088%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MLYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Susquehanna Portfolio Strategies, LLC holds $399,265,861 across 121 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
90,928 | $45,166,665 | |
| 2 | MRNA |
Moderna, Inc.
|
471,043 | $32,987,141 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
211,017 | $18,347,928 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
226,869 | $16,897,203 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
273,562 | $15,653,217 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
166,503 | $13,032,189 | |
| 7 | EXEL |
Exelixis, Inc.
|
229,749 | $12,500,643 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
22,003 | $11,814,510 |
All Filings in MLYS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,115,512 | 78,092 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,833,958 | 78,092 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,961,248 | 78,092 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,180,143 | 161,134 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $289,730 | 18,245 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||